143 related articles for article (PubMed ID: 9849422)
1. 10 years' neuroblastoma screening in Europe: preliminary results of a clinical and biological review from the Study Group for Evaluation of Neuroblastoma Screening in Europe (SENSE).
Erttmann R; Tafese T; Berthold F; Kerbl R; Mann J; Parker L; Schilling F; Ambros P; Christiansen H; Favrot M; Kabisch H; Hero B; Philip T
Eur J Cancer; 1998 Aug; 34(9):1391-7. PubMed ID: 9849422
[TBL] [Abstract][Full Text] [Related]
2. Evolving significance of prognostic markers associated with treatment improvement in patients with stage 4 neuroblastoma.
Mora J; Gerald WL; Qin J; Cheung NK
Cancer; 2002 May; 94(10):2756-65. PubMed ID: 12173347
[TBL] [Abstract][Full Text] [Related]
3. [N-myc gene copies in children with neuroblastoma and its clinical significance].
Ma XL; Gong LP; Zhou CJ; Zhang DW; Jin M; Wang HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1447-51. PubMed ID: 23257451
[TBL] [Abstract][Full Text] [Related]
4. Screening for neuroblastoma: a review of the evidence.
Chamberlain J
J Med Screen; 1994 Jul; 1(3):169-75. PubMed ID: 8790511
[TBL] [Abstract][Full Text] [Related]
5. Insights into infant neuroblastomas based on an analysis of neuroblastomas detected by mass screening at 6 months of age in Japan.
Suita S; Tajiri T; Higashi M; Tanaka S; Kinoshita Y; Takahashi Y; Tatsuta K
Eur J Pediatr Surg; 2007 Feb; 17(1):23-8. PubMed ID: 17407017
[TBL] [Abstract][Full Text] [Related]
6. The angiogenic growth factors HGF and VEGF in serum and plasma from neuroblastoma patients.
Sköldenberg EG; Larsson A; Jakobson A; Hedborg F; Kogner P; Christofferson RH; Azarbayjani F
Anticancer Res; 2009 Aug; 29(8):3311-9. PubMed ID: 19661350
[TBL] [Abstract][Full Text] [Related]
7. Survival from non-stage 4 neuroblastoma without cytotoxic therapy: an analysis of clinical and biological markers.
Cheung NK; Kushner BH; LaQuaglia MP; Kramer K; Ambros P; Ambros I; Ladanyi M; Eddy J; Bonilla MA; Gerald W
Eur J Cancer; 1997 Oct; 33(12):2117-20. PubMed ID: 9516865
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of DNA di-tetraploidy in neuroblastoma.
Ladenstein R; Ambros IM; Pötschger U; Amann G; Urban C; Fink FM; Schmitt K; Jones R; Slociak M; Schilling F; Ritter J; Berthold F; Gadner H; Ambros PF
Med Pediatr Oncol; 2001 Jan; 36(1):83-92. PubMed ID: 11464912
[TBL] [Abstract][Full Text] [Related]
9. Regression and progression in neuroblastoma. Does genetics predict tumour behaviour?
Ambros PF; Ambros IM; Strehl S; Bauer S; Luegmayr A; Kovar H; Ladenstein R; Fink FM; Horcher E; Printz G
Eur J Cancer; 1995; 31A(4):510-5. PubMed ID: 7576955
[TBL] [Abstract][Full Text] [Related]
10. Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p.
Mora J; Cheung NK; Kushner BH; LaQuaglia MP; Kramer K; Fazzari M; Heller G; Chen L; Gerald WL
J Mol Diagn; 2000 Feb; 2(1):37-46. PubMed ID: 11272900
[TBL] [Abstract][Full Text] [Related]
11. Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas.
Nakagawara A; Zaizen Y; Ikeda K; Suita S; Ohgami H; Nagahara N; Sera Y; Akiyama H; Kawakami K; Uchino J
Cancer; 1991 Nov; 68(9):2037-44. PubMed ID: 1913552
[TBL] [Abstract][Full Text] [Related]
12. Neuroblastoma mass screening: the arguments for and against.
Treuner J; Schilling FH
Eur J Cancer; 1995; 31A(4):565-8. PubMed ID: 7576969
[TBL] [Abstract][Full Text] [Related]
13. Screening for neuroblastoma in France: methodological aspects and preliminary observations.
Chauvin F; Mathieu P; Frappaz D; Lasset C; Favrot MC; Greffe J; Esteve J; Thiesse P; Combaret V; Chauvot P; Boschetti R; David L; Brunat-Mentigny M; Philip T
Med Pediatr Oncol; 1997 Feb; 28(2):81-91. PubMed ID: 8986143
[TBL] [Abstract][Full Text] [Related]
14. [Long-term follow-up of neuroblastoma in children less than 18 months of age].
Zhao J; Pan C; Xu M; Zhou M; Gao YJ; Hu WT; Tang JY
Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):754-759. PubMed ID: 29050113
[No Abstract] [Full Text] [Related]
15. Biological aspects of neuroblastomas identified by mass screening in Quebec.
Brodeur GM; Look AT; Shimada H; Hamilton VM; Maris JM; Hann HW; Leclerc JM; Bernstein M; Brisson LC; Brossard J; Lemieux B; Tuchman M; Woods WG
Med Pediatr Oncol; 2001 Jan; 36(1):157-9. PubMed ID: 11464873
[TBL] [Abstract][Full Text] [Related]
16. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study.
Maris JM; Weiss MJ; Guo C; Gerbing RB; Stram DO; White PS; Hogarty MD; Sulman EP; Thompson PM; Lukens JN; Matthay KK; Seeger RC; Brodeur GM
J Clin Oncol; 2000 May; 18(9):1888-99. PubMed ID: 10784629
[TBL] [Abstract][Full Text] [Related]
17. Features and outcome of neuroblastoma detected before birth.
Granata C; Fagnani AM; Gambini C; Boglino C; Bagnulo S; Cecchetto G; Federici S; Inserra A; Michelazzi A; Riccipetitoni G; Rizzo A; Tamaro P; Jasonni V; De Bernardi B
J Pediatr Surg; 2000 Jan; 35(1):88-91. PubMed ID: 10646781
[TBL] [Abstract][Full Text] [Related]
18. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
19. Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease.
Mora J; Cheung NK; Chen L; Qin J; Gerald W
Cancer; 2001 Jan; 91(2):435-42. PubMed ID: 11180092
[TBL] [Abstract][Full Text] [Related]
20. Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: results of the French NBL 90 Study. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP).
Rubie H; Delattre O; Hartmann O; Combaret V; Michon J; Bénard J; Peyroulet MC; Plantaz D; Coze C; Chastagner P; Baranzelli MC; Frappaz D; Lemerle J; Sommelet D
Eur J Cancer; 1997 Oct; 33(12):1917-22. PubMed ID: 9516824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
